

Duration of antibiotic treatment for Gram-negative bacteremia – Systematic review and individual participant data (IPD) meta-analysis



Adi Turjeman,^{a,b,*} Elodie von Dach,^{c,d} José Molina,^{e,f,g} Erica Franceschini,^h Fidi Koppel,ⁱ Dana Yelin,^j Yael Dishon-Benattar,^{i,k} Cristina Mussini,^h Jesús Rodríguez-Baño,^{g,l} José Miguel Cisneros,^{e,f,g} Angela Huttner,^c Mical Paul,^{i,k} Leonard Leibovici,^{a,b} and Dafna Yahav^{bj}



^aResearch Authority, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

^bSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

^cFaculty of Medicine, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland

^dFaculty of Medicine, Clinical Research Center, Geneva University Hospitals, Geneva, Switzerland

^eClinical Unit of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, Seville, Spain

^fInstitute of Biomedicine of Seville (IBIS), Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, Seville, Spain

^gCenter for Biomedical Research Network (CIBER) on Infectious Diseases, Madrid, Spain

^hClinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy

ⁱInfectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel

^jInfectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel

^kThe Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

^lClinical Unit of Infectious Diseases and Microbiology, Virgen Macarena University Hospital; Department of Medicine, School of Medicine, University of Seville; and Biomedicine Institute of Seville/CSIC, Seville, Spain

Summary

Background We aim to compare the effect of short versus long treatment duration in Gram-negative bacteremia on all-cause mortality in pre-specified sub-groups.

Methods Individual participant data meta-analysis of randomized controlled trials (RCTs) comparing short (≤ 7) versus longer (> 7 days) antibiotic treatment for Gram-negative bacteremia. Participants were adults (≥ 18 years), with Gram-negative bacteremia during hospital stay. We searched PubMed, Cochrane Central Register of Controlled Trials, and Web of Science to identify trials conducted up to May 2022. Primary outcome was 90-day all-cause mortality. Secondary outcomes were 30-day mortality, relapse of bacteremia, length of hospital stay, readmission, local or distant infection complications, adverse events, and resistance emergence.

Outcomes were assessed in pre-specified subgroups: women vs men; non-urinary vs urinary source; presence vs absence of hypotension on initial presentation; immunocompromised patients versus non-immunocompromised patients, and age (above/below 65). Fixed-effect meta-analysis model was used to estimate pooled odds ratio (OR) and 95% confidence interval (CI). All three trials had low risk of bias for allocation generation and concealment.

Findings Three RCTs (1186 patients) were included; 1121 with *enterobacterales* bacteremia. No significant difference in mortality was demonstrated between 7- and 14-days treatment (90-day mortality: OR 1.08, 95% CI 0.73–1.58; 30-day mortality: 1.08, 0.62–1.91). Relapse (1.00, 0.50–1.97); length of hospital stay ($P = 0.78$); readmission (0.96, 0.80–1.22); and infection complications (local: 1.62 0.76–3.47; distant: 2.00, 0.18–22.08), were without significant difference, and so were adverse events or resistance emergence.

No significant difference in clinical outcomes between 7 and 14 days of antibiotics was demonstrated in the sub-groups of gender, age, hemodynamic status, immune status, and source of infection.

Interpretation For patients hemodynamically stable and afebrile at 48 h prior to discontinuation, seven days of antibiotic therapy for *enterobacterales* bacteremia result in similar outcomes as 14 days, in terms of mortality, relapse, length of hospital stay, complications of infection, resistance emergence, and adverse events. These results apply for any adult age group, gender, source of infection, immune status, and hemodynamic status on presentation.

Funding There was no funding source for this study.

eClinicalMedicine
2023;55: 101750

Published Online 1

December 2022

<https://doi.org/10.1016/j.eclinm.2022.101750>

*Corresponding author. Research Authority, Beilinson hospital, Rabin Medical Center, 39 Jabotinski Road, Petah-Tikva, 49100, Israel.
E-mail address: aditur88@gmail.com (A. Turjeman).

Copyright © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords: Individual patient data meta-analysis; Treatment duration; Gram-negative bacteremia; Antibiotics; Resistance

Research in context

Evidence before this study

Previous retrospective data has shown inconclusive results regarding optimal treatment duration for Gram-negative bacteremia. We performed a systematic literature search for randomized controlled trials (RCTs) comparing treatment duration for Gram-negative bacteremia. We used three databases (PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science) and three clinical trial registries (ISRCTN registry, Clinicaltrials.gov and the European Union Clinical Trials Register) to search for RCTs conducted up to May 2022. No language or publication restrictions were applied. Search terms were 'duration OR days' and 'antibiotic' and 'bloodstream OR bacteremia OR bacteremia'.

We found three recent RCTs, that have all demonstrated non-inferiority for shorter antibiotic courses for Gram-negative bacteremia, but were underpowered for select subgroups such as: men vs women, non-urinary source of the infection, patients presenting with hemodynamic instability, immunocompromised patients, and the elderly.

Added value of this study

Our individual patient data meta-analysis has combined the largest comparison of shorter vs. longer duration of antibiotic treatment for Gram-negative bacteremia to date. It has reproduced the overall findings of each of the separated RCTs showing that a 7-day treatment is non-inferior to 14-days in terms of mortality and other clinical outcomes. Analyzing this large database for subgroup analysis, we did not find a significant difference in clinical outcomes between 7 and 14 days of antibiotics in the subgroups of women vs men; non urinary vs urinary source of bacteremia; presence vs absence of hypotension on initial presentation; immunosuppression; and age (above/below 65).

Implications of all available evidence

Shorter courses of antibiotic therapy may be encouraged in eligible patients and may shorten length of inpatient stay, decrease antibiotic exposure and reduce costs without impacting mortality or other adverse outcomes.

Introduction

Gram-negative bacteremia is common in both community and health care settings, with a significant increase in incidence described for some Gram-negative bacteria in recent years.^{1,2} Prolonged duration of antibiotic therapy for such common infections may lead to increased resistance emergence; adverse events and secondary infections, including *Clostridioides difficile* infection; prolonged hospital-stay; and excess cost.^{3,4}

Although recent randomized controlled trials (RCTs) have demonstrated the non-inferiority of shorter antibiotic courses for Gram-negative bacteremia,^{5–7} prolonged courses are still commonly used and current guidelines still recommend the range of 7–14 days.^{4,8} In addition, it is unclear whether shorter courses of antibiotics are appropriate for specific sub-groups of patients, such as those with non-urinary source of bacteremia; intensive care patients, elderly, and others.

Observational design is a limited tool for evaluating duration of therapy due to confounding by indication and immortal time bias issues.⁹ Thus, RCTs are the preferred design to answer this question. Individual participant data (IPD) meta-analysis of RCTs is considered to be the gold standard of systematic review.¹⁰ IPD

meta-analysis advantages (among others) are narrowing the confidence intervals, and increasing the power to evaluate treatment effect in specific sub-groups of patients.¹¹

We performed an IPD meta-analysis of RCTs evaluating short (≤ 7 days) versus longer (> 7 days) antibiotic treatment for Gram-negative bacteremia. We aimed to explore outcomes in several pre-specified sub-groups of patients. We hypothesized no significant difference between short and long antibiotic course for either of the sub-groups.

Methods

This IPD systematic review and meta-analysis was conducted and reported according to the PRISMA-IPD Statement,¹² and Cochrane instructions for IPD-MA.¹³ Considering the priority of the results for decision-making, and taking into account expected new evidence from a large ongoing trial in the topic, we conduct this review as a living systematic review.^{14,15} For the living systematic review we will repeat the search every 12 months. Updates of the meta-analysis will be conducted when new evidence that is likely to influence the results will be identified.

We included RCTs comparing short (≤ 7 days) versus longer (> 7 days) antibiotic treatment for Gram-negative bacteremia. Participants were hospitalized adults (≥ 18 years), with Gram-negative bacteremia, as defined in individual trials. We included only trials evaluating patients with Gram-negative bacteremia as their target population. Trials evaluating various infection types (e.g., pneumonia, urinary tract infection), and reporting bacteremic patients as a sub-group were not included. We excluded trials addressing source of bacteremia requiring prolonged treatment (endocarditis/endovascular infections; necrotizing fasciitis; osteomyelitis; abdominal abscesses and other unresolved abdominal sources requiring source control (surgery/drainage); central nervous system infections; empyema; any uncontrolled focus of infection (undrained abscess/deep seated intra-abdominal infection, undrained moderate to severe hydronephrosis). We also excluded patients with intracellular pathogens including *Salmonella* spp. and *Brucella* spp.

Interventions tested were antibiotics with in vitro activity against the pathogen for ≤ 7 vs > 7 days. Any choice and route of administration of antibiotics (oral or intravenous) were eligible for inclusion. Any source of bacteremia not requiring prolonged treatment (urinary tract infection, pneumonia, etc.) and any place of acquisition (community or hospital) were eligible for inclusion.

Primary outcome was 90-day all-cause mortality.¹⁶ Secondary outcomes included 30-day all-cause mortality; relapse of bacteremia; length of hospital stay; readmissions; local suppurative and distant complications; restarting of Gram-negative-directed antibiotic therapy; emergence of resistance to study antibiotics; functional capacity and time to return to baseline capacity; new clinically or microbiologically documented infection; and adverse events: any diarrhea, *C. difficile* associated diarrhea, acute kidney injury, and rash (for secondary outcomes definitions, see [Appendix](#)).

We pre-planned to extract data regarding the following sub-groups: men versus women; patients with a non-urinary source of infection vs patients with urinary tract infection (UTI); presence vs absence of hypotension on initial presentation (hypotension was defined as systolic blood pressure of less than 100 mmHg), immunocompromised patients versus non-immunocompromised patients, and elderly (age ≥ 65 years) versus younger patients.

Immunosuppression was defined as treatment with immunosuppressive drugs (including prednisone ≥ 20 mg/day or equivalent, biological agents) due to any reason, active chemotherapy, solid organ transplantation, and stem cell transplantation. The following immunosuppressive conditions were excluded: HIV infection with CD4 cell count $\leq 500/\mu\text{l}$, and neutropenia (absolute neutrophil count $\leq 500/\mu\text{l}$) in the 48 h prior to randomization.

Information sources and search strategy

We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to identify trials conducted up to May 2022. Search term combined the Cochrane filter for RCTs¹⁷ with the terms 'duration OR days' and 'antibiotic' and 'bloodstream OR bacteremia OR bacteraemia', restricted to adults by PubMed filter. We applied no language or publication restrictions. References of all included trials were searched for additional relevant trials. The investigators of eligible trials were contacted to ask for acquaintance with similar trials. We also searched relevant conference proceedings, as well as ongoing trial databases for unpublished trials.

Data collection and analysis

Studies were fully reviewed (titles, abstract and full texts) and appraised by two investigators independently. Conflicts were resolved by consultation with an independent third reviewer. First authors of the trials identified were invited to share their trials' data through email, and consenting authors were asked to participate and send their data anonymized in an encrypted table. Each participating site received the permission of the local ethics committee to transfer the data according to local regulations. Queries regarding data were resolved by communication with the authors of each trial and discrepancies between published and raw data were checked with them.

Risk of bias of included trials was assessed by two review authors independently using domain-based evaluation as recommended in the Cochrane Handbook for Systematic Reviews of Interventions.¹⁷

Statistical analysis

Baseline characteristic of included trials are presented as frequencies (percentages) for categorical variables, and interquartile range (IQR, 25–75 percentiles) for non-normally distributed continuous variables.

Difference in outcomes rate between 7 and 14 days of antibiotic therapy for Gram-negative bacteremia were examined. An analysis of outcomes by several pre-specified sub-groups of patients was also performed. Generalized linear models (GLM) were used for the comparison of continuous variables between trials. For categorical variables, the fixed-effect meta-analysis model (Mantel-Haenszel method) was used to estimate pooled odds ratio and associated 95% confidence interval. The Breslow–Day test for homogeneity of odds ratios was performed to test for between trials differences. The analysis was performed following the intention-to-treat principle, including all patients according to the treatment group assigned at the time of randomization. We also performed a per-protocol analysis for the primary outcome.

Statistical analyses were performed using IBM SPSS Statistics, version 27.

Role of the funding source

There was no funding source for this study.

Results

The study flow chart is presented in Fig. 1. Three trials met our inclusion criteria, all were investigator-initiated, and compared an antibiotic duration of seven versus fourteen days for Gram-negative bacteremia.⁵⁻⁷ One of these three trials included a C-reactive protein (CRP)-based duration arm that was excluded from the analysis,⁶ leaving overall 1186 randomized patients (1182 evaluable patients; Yahav et al. 604 patients⁵; von Dach et al. 334 patients⁶; and Molina et al. 248 patients⁷). Trials’ characteristics are detailed in Table 1. The most common source of bacteremia in the original trials was UTI (411/604, 68%; 213/334, 64%, and 136/248, 55% of

patients in the different trials). Accordingly, the vast majority of causative bloodstream isolates were *enterobacterales* (95%, 1125/1186), with two trials including only patients with *enterobacterales* bacteremia,^{6,7} and a third trial allowing other Gram-negatives.⁵ In the three included trials, choice and route of administration of antibiotics was at the discretion of the treating physician. Risk of bias assessment of the included trials is detailed in Fig. 2. All three trials had low risk of bias for allocation generation and concealment; all three were open-label.

Overall, 592 patients were included for evaluation in the short (7 days) arm and 590 in the long (14 days) arm. The Breslow–Day test showed no heterogeneity of odds ratios between trials. For the outcome of mortality, no significant difference was demonstrated for either 90- or 30-day mortality between arms (90 days mortality 7 days: 60/592 (10.1%), 14 days: 56/590 (9.5%) - OR 1.08, 95% CI 0.73–1.58; 30d mortality 7 days: 26/592 (4.4%), 14 days: 24/590 (4.1%) - OR 1.08, 95% CI 0.62–1.91 (with OR > 1 favoring 14 days).




Fig. 1: Study flowchart.

	Yahav et al. (2018)	von Dach et al. (2020)	Molina et al. (2021)
Trial characteristics			
Design	Investigator-initiated randomized controlled trial	Investigator-initiated randomized controlled trial	Investigator-initiated randomized controlled trial
Study period	2013–2017	2017–2019	2014–2016
Inclusion criteria	Adults with growth of Gram-negative bacteria in one or more blood cultures, hemodynamically stable and afebrile for at least 48 h.	Adults with growth of Gram-negative fermenters in at least one blood culture and treatment with a microbiologically efficacious antibiotic.	Adults with a diagnosis of <i>enterobacterales</i> bloodstream infections with appropriate source control.
Exclusion criteria	Sources of infection requiring prolonged treatment, fever or hemodynamic instability in the 48 h prior to randomization, uncontrolled focus of infection, polymicrobial growth involving Gram-positive bacteria, specific pathogens (<i>Brucella</i> , <i>Salmonella</i>), or specific immunosuppression (human immunodeficiency virus, neutropenia).	Fever or hemodynamic instability in the 24 h prior to recruitment, severe immunosuppression, bacteremia with nonfermenting bacilli or polymicrobial, gram-positive growth, recurrent bacteremia, or complicated infections.	Pregnancy, noncontrolled source of infection and no expectation of being controlled in the subsequent 24 h, patients undergoing chemotherapy with neutropenia <500 cells/mm ³ expected for more than 7 days, infections requiring prolonged antibiotic treatment, infections caused by a carbapenemase producing member of the Enterobacterales, polymicrobial bacteraemia, and expectation of survival <48 h.
Timing of randomization	At least 48 h without fever and hemodynamically stable and until day 7 from positive culture	Day 5 from first positive culture	<48 h since pathogen identification
Number randomized	604	504	248
Primary outcome of the original study	Composite at 90 days of mortality, relapse, complications, and readmission or extended hospitalization	Composite at 30 days of mortality, relapse, distal complications, and the restarting of antibiotics for suspected relapse	Number of days of antibiotic treatment required at the end of follow-up.
Patient characteristics			
Age (median, interquartile range)	71 (61–80)	79 (68–86)	67 (53–77)
Gender- women	319/604 (53%)	306/504 (61%)	118/248 (48%)
Immunocompromised patients ^a			
Malignancy	159/604 (26%)	NR	64/248 (26%)
Immunosuppressive drugs	150/604 (25%)	None	31/248 (12.5%)
Solid-organ transplant	51/604 (8.5%)	None	11/248 (4.5%)
Stem-cell transplant	5/604 (0.8%)	None	NR
Infection characteristics			
Source of infection			
Urinary tract	411/604 (68%)	335/504 (66%)	136/248 (55%)
Abdominal	71/604 (12%)	80/504 (16%)	34/248 (14%)
Respiratory	24/604 (4%)	25/504 (5%)	15/248 (6%)
Central venous catheter	38/604 (6%)	8/504 (2%)	30/248 (12%)
Skin and soft tissue	9/604 (2%)	4/504 (1%)	3/248 (1%)
Unknown	51/604 (8%)	52/504 (10%)	29/248 (12%)
Presence of hypotension on initial presentation (SBP<100)	186/604 (31%)	169/504 (34%)	63/244 (26%)
Hospital acquired	176/604 (29%)	135/504 (27%)	81/247 (33%)

(Table 1 continues on next page)

	Yahav et al. (2018)	von Dach et al. (2020)	Molina et al. (2021)
(Continued from previous page)			
Bacteria type			
Escherichia coli	380/604 (63%)	377/502 (74%)	155/247 (63%)
Klebsiella spp	80/604 (13%)	68/502 (14%)	46/247 (19%)
Other	82/604 (14%)	45/502 (9%)	46/247 (19%)
Enterobacteriaceae			
Non-fermenting bacilli	61/604 (10%)	None	None
Other ^b	1/604 (~0%)	12/502 (2%)	None
Recurrent bacteremia (previous 60 days)	NR	None	NR
Multidrug resistant (MDR) bacteria ^c	109/604 (18%)	40/504 (8%)	41/248 (16.5%)

SBP – systolic blood pressure. ^aThe followings were excluded: HIV infection with CD4 cell count ≤500/μl, hematopoietic stem-cell transplantation in the first month after transplantation and at any time before engraftment, neutropenia in the 48 h prior to randomization, receipt of high-dose steroids (>40 mg prednisone or its equivalent) daily for >2 weeks, in the two weeks prior to randomization. ^bBacteroides fragilis, Haemophilus influenzae. ^cMultidrug resistance (MDR) was defined as: • Extended spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae demonstrating resistance to oxymino-beta-lactam substrates (cefotaxime and ceftazidime) were defined as ESBL positive. • Pseudomonas spp. resistant to three or more of the following antimicrobial agents: antipseudomonal penicillins (e.g., piperacillin), antipseudomonal cephalosporins (e.g., ceftazidime), fluoroquinolones (e.g., ciprofloxacin), carbapenems (imipenem, meropenem), and aminoglycosides. • Acinetobacter spp. resistant to three or more of the following agents: imipenem (or meropenem), levofloxacin (or other fluoroquinolones), ceftazidime, colistin, tobramycin (or other aminoglycosides), and piperacillin-tazobactam.

Table 1. Baseline characteristic of included trials.

Overall, 1041 patients (88%) were included in the per-protocol analysis. For the primary outcome of 90-day mortality, no significant difference was demonstrated between arms (OR 1.26, 95% CI 0.81–1.95).

Other components of the primary outcomes from the trials were without significant difference between arms (Table 2). These included relapse of bacteremia, length of hospital stay, readmissions at 30 days; and distal complications and local suppurative complications at 90 days (Table 2). Other components of the primary outcomes were reported by individual trials, including restart of targeted antibiotics until 90 days by von Dach et al., without difference between arms (7-days: 9/169, 56% vs 14-days: 9/165, 56%)⁶; and absence of clinical cure (i.e. no resolution of signs and symptoms) by Molina et al., with no significant difference between arms (7-days: 8/110, 7.3% vs 14-days: 12/122, 9.8%).⁷

Emergence of resistance to study antibiotic was reported from two trials for a follow up of up to 90 days, reporting 36/592 cases (6%) in the short arm and 29/590 cases (5%) in the long arm, without significant difference (OR 1.23, 95% CI 0.74–2.04). New clinically or microbiologically documented infection and functional capacity were reported from only one trial. This trial reported no difference in new infections between arms, and significantly shorter time to return to baseline functional capacity in the 7 days arm.⁵ As expected, duration of antibiotic therapy for the index bacteremia was significantly shorter in the seven-day arm. Adverse events that were reported from at least two trials included diarrhea, C. difficile associated diarrhea, rash and acute kidney injury. All were without significant difference between short and long therapy (Table 2).

An analysis of outcomes by subgroups, including gender, source of infection (UTI vs non-UTI), blood pressure at presentation (Systolic blood pressure ≥100 mmHg or <100 mmHg), immune status, and age (≥65 years vs < 65) is presented in Table 3. Overall, 1182 (100%) patients were included in the subgroup analysis according to gender, infection source, and age; 1180 (~100%) patients were included in the subgroup analysis according to hemodynamic status; and 850 (72%) patients were included in the subgroup analysis according to immune status. For the outcomes of 90- or 30-day mortality, relapse of bacteremia, and readmissions at 30 days, no significant difference was demonstrated between 7 and 14 days among any of the subgroups (gender, source of infection, hemodynamic status, immune status, and age).

Discussion

In this individual patient data meta-analysis of three RCTs, evaluating overall 1182 patients, we found no significant difference in 90- or 30-day mortality between 7 and 14 days of antibiotic therapy for Gram-negative bacteremia. Other patient related outcomes, such as



Fig. 2: Risk of bias assessment.

relapse of bacteremia, length of hospital stay, readmission, and local or distant complications, were also demonstrated to be without significant difference. No

difference in emergence of resistance or adverse events was either demonstrated between short and long therapy arms, though the number of events was low and the follow up duration limited to 90 days.

Analyzing this large database for subgroup analysis, we also did not find a significant difference in clinical outcomes between 7 and 14 days of antibiotics in the subgroups of women vs men; non urinary vs urinary source of bacteremia; presence vs absence of hypotension on initial presentation; immunocompromised patients vs non-immunocompromised patients; and age (above/below 65).

Shorter antibiotic therapy for Gram-negative bacteremia has been demonstrated to have similar outcomes to longer duration in several observational studies, mostly comparing 5–10 days to longer regimens.^{18–30} Mortality, relapse/recurrence, clinical success, and superinfection rates were similar between longer and shorter therapy in most studies, though some demonstrated higher rates of superinfection^{18,27} or resistance emergence²³ with longer therapy; while others reported higher rates of re-initiation of antibiotics and *C. difficile* with shorter regimen.²⁸

Concomitantly, three RCTs demonstrated non-inferiority of 7 vs 14 days of antibiotic therapy for hemodynamically stable patients with mainly *enterobacterales* bacteremia. The strength of this individual patient data meta-analysis is by allowing a larger sample size to test the effect of duration of therapy for specific subgroups of patients. In this meta-analysis, short versus long therapy had similar outcomes among 425 patients with non-urinary source of infection, 801 elderly patients (aged ≥65) and 359 patients with low

Variable	Yahav et al.		von Dach et al.		Molina et al.		Mantel-Haenszel OR (95% CI)	Breslow-Day P value
	7 days (n = 306)	14 days (n = 298)	7 days (n = 169)	14 days (n = 165)	7 days (n = 117)	14 days (n = 127)		
90-d mortality	36 (11.8)	32 (10.7)	14 (8.3)	9 (5.5)	10 (8.5)	15 (11.8)	1.08 (0.73–1.58)	0.41
30-d mortality	16 (5.2)	12 (4.0)	6 (3.6)	4 (2.4)	4 (3.4)	8 (6.3)	1.08 (0.62–1.91)	0.40
Relapse of bacteremia –30d	8 (2.6)	8 (2.7)	2 (1.2)	3 (1.8)	7 (5.9)	6 (4.7)	1.00 (0.50–1.97)	0.82
Readmissions - 30d	74 (24.2)	79 (26.5)	14 (8.3)	9 (5.5)	11 (9.2)	12 (9.3)	0.98 (0.73–1.33)	0.49
Hospital length of stay, Median (IQR)	1 (0–4)	1 (0–4)	4 (1.3–10)	4 (1–11)	4 (0–9)	3 (0–8)	–	0.71*
Duration of antibiotic therapy, Median (IQR)	5 (4–13)	12 (10–16)	7 (6–9)	13 (9–14)	7 (7–14)	14 (14–16)	–	0.39*
Local suppurative complications 90d	16 (5.2)	10 (3.4)	2 (1.2)	1 (0.6)	–	–	1.62 (0.76–3.47)	0.87
Distal complications 90d	2 (0.7)	1 (0.3)	0 (0.0)	0 (0.0)	–	–	2.00 (0.18–22.08)	–
Emergence of resistance to study antibiotic –90d	33 (10.8)	29 (9.7)	3 (1.8)	0 (0.0)	–	–	1.23 (0.74–2.04)	0.11
Diarrhea	18 (5.9)	24 (8.1)	–	–	2 (1.7)	3 (2.3)	0.73 (0.40–1.33)	1.00
<i>Clostridioides difficile</i> infection	2 (0.7)	2 (0.7)	2 (1.2)	4 (2.4)	–	–	0.65 (0.18–2.31)	0.60
Rash	2 (0.7)	4 (1.3)	–	–	1 (0.8)	4 (3.1)	0.37 (0.10–1.41)	0.67
Acute kidney injury	14 (4.6)	12 (4.0)	–	–	3 (2.5)	1 (0.8)	1.33 (0.64–2.77)	0.37

Data are presented as no. (%). OR – odds ratio; CI – confidence interval; IQR - interquartile range. *P value by General linear models.

Table 2: The association between study arm and outcomes, stratified by trial (For categorical variables, fixed-effect meta-analysis model, Mantel-Haenszel method. Homogeneity of odds ratios between trials was evaluated with the Breslow-Day test).

		Yahav et al.		Von Dach et al.		Molina et al.		Mantel-Haenszel OR (95% CI)	Breslow-Day P value	
		7 days (n = 306)	14 days (n = 298)	7 days (n = 169)	14 days (n = 165)	7 days (n = 117)	14 days (n = 127)			
90-d mortality	All patients	36/306 (11.8)	32/298 (10.7)	14/169 (8.3)	9/165 (5.5)	10/117 (8.5)	15/127 (11.8)	1.08 (0.73-1.58)	0.41	
	Gender	Women	16/156 (10.3)	14/163 (8.6)	10/107 (9.3)	5/94 (5.3)	6/59 (10.2)	5/59 (8.5)	1.34 (0.77-2.34)	0.64
		Men	20/150 (13.3)	18/135 (13.3)	4/62 (6.5)	4/71 (5.6)	4/58 (6.9)	10/68 (14.7)	0.88 (0.51-1.50)	
	Source of infection	Non UTI	11/86 (12.8)	6/107 (5.6)	5/68 (7.4)	5/53 (9.4)	8/48 (16.7)	9/63 (14.3)	1.37 (0.73-2.56)	0.12
		UTI	25/220 (11.4)	26/191 (13.6)	9/101 (8.9)	4/112 (3.6)	2/69 (2.9)	6/64 (9.4)	0.94 (0.58-1.52)	
	SBP	SBP≥100	22/215 (10.2)	18/202 (8.9)	5/106 (4.7)	5/117 (4.3)	8/88 (9.1)	8/93 (8.6)	1.15 (0.70-1.90)	0.64
		SBP<100	14/91 (15.4)	14/95 (14.7)	9/63 (14.3)	4/47 (8.5)	2/29 (6.9)	7/34 (20.6)	0.96 (0.53-1.74)	
	Age	Age<65	5/98 (5.1)	12/102 (11.8)	0/28 (0.0)	1/39 (2.6)	4/57 (7.0)	5/57 (8.8)	0.52 (0.23-1.18)	0.20
		Age≥65	31/208 (14.9)	20/196 (10.2)	14/141 (9.9)	8/126 (6.3)	6/60 (10.0)	10/70 (14.3)	1.33 (0.85-2.07)	
	Immunosuppression	No	27/237 (11.4)	22/217 (10.1)	/	/	6/100 (6.0)	12/113 (10.6)	0.95 (0.57-1.57)	0.64
Yes		9/69 (13.0)	10/81 (12.3)	/	/	4/17 (23.5)	3/14 (21.4)	1.12 (0.49-2.58)		
30-d mortality	All patients	16/306 (5.2)	12/298 (4.0)	6/169 (3.6)	4/165 (2.4)	4/117 (3.4)	8/127 (6.3)	1.08 (0.62-1.91)	0.40	
	Gender	Women	7/156	7/163 (4.3)	4/107 (3.7)	2/94 (2.1)	3/59 (5.1)	2/59 (3.4)	1.26 (0.56-2.82)	0.49
		Men	9/150 (6.0)	5/135 (3.7)	2/62 (3.2)	2/71 (2.8)	1/58 (1.7)	6/68 (8.8)	0.93 (0.42-2.09)	
	Source of infection	Non UTI	7/86 (8.1)	5/107 (4.7)	2/68 (2.9)	2/53 (3.8)	3/48 (6.3)	3/63 (4.8)	1.35 (0.57-3.18)	0.40
		UTI	9/220 (4.1)	7/191 (3.7)	4/101 (4.0)	2/112 (1.9)	1/69 (1.4)	5/64 (7.8)	0.94 (0.44-2.00)	
	SBP	SBP≥100	13/215 (6.0)	11/202 (5.4)	3/106 (2.8)	2/117 (1.7)	2/88 (2.3)	3/93 (3.2)	1.14 (0.57-2.27)	0.76
		SBP<100	3/91 (3.3)	1/95 (1.1)	3/63 (4.8)	2/47 (4.3)	2/29 (6.9)	5/34 (14.7)	0.96 (0.35-2.62)	
	Age	Age<65	7/98 (7.1)	2/102 (2.0)	0/28 (0.0)	0/39 (0.0)	2/57 (3.5)	2/57 (3.5)	2.51 (0.76-8.29)	0.29
		Age≥65	9/208 (4.3)	10/196 (5.1)	6/141 (4.3)	4/126 (3.2)	2/60 (3.3)	6/70 (8.6)	0.81 (0.42-1.56)	
	Immunosuppression	No	11/237 (4.6)	12/217 (5.5)	/	/	3/100 (3.0)	7/113 (6.2)	0.71 (0.35-1.44)	0.06
Yes		5/69 (7.2)	0/81 (0.0)	/	/	1/17 (5.9)	1/14 (7.1)	7.05 (0.83-59.80)		
Relapse of bacteremia -30d	All patients	8/306 (2.6)	8/298 (2.7)	2/169 (1.2)	3/165 (1.8)	7/117 (5.9)	6/127 (4.7)	1.00 (0.50-1.97)	0.82	
	Gender	Women	2/156 (1.3)	6/163 (3.7)	2/107 (1.9)	3/94 (3.2)	4/59 (6.8)	2/59 (3.4)	0.71 (0.28-1.78)	0.33
		Men	6/150 (4.0)	2/135 (1.5)	0/62 (0.0)	0/71 (0.0)	3/59 (5.1)	4/68 (5.9)	1.53 (0.54-4.37)	
	Source of infection	Non UTI	1/86 (1.2)	3/107 (2.8)	1/68 (1.5)	2/53 (3.8)	2/48 (4.2)	3/63 (4.8)	0.54 (0.16-1.83)	0.88
		UTI	7/220 (3.2)	5/191 (2.6)	1/101 (1.0)	1/112 (0.9)	5/70 (7.1)	3/64 (4.7)	1.37 (0.58-3.24)	
	SBP	SBP≥100	6/215 (2.8)	8/202 (4.0)	1/106 (0.9)	2/117 (1.7)	5/88 (5.7)	3/93 (3.2)	0.93 (0.42-2.06)	0.61
		SBP<100	2/91 (2.2)	0/95 (0.0)	1/63 (1.6)	1/47 (2.1)	2/29 (6.9)	3/34 (8.8)	1.21 (0.32-4.57)	
	Age	Age<65	3/98 (3.1)	2/102 (2.0)	0/28 (0.0)	1/39 (2.6)	4/57 (7.0)	4/57 (7.0)	1.09 (0.37-3.16)	0.91
		Age≥65	5/208 (2.4)	6/196 (3.1)	2/141 (1.4)	2/126 (1.6)	3/61 (4.9)	2/70 (2.9)	0.96 (0.39-2.32)	
	Immunosuppression	No	7/237 (3.0)	7/217 (3.2)	/	/	7/101 (6.9)	3/113 (2.7)	1.38 (0.61-3.16)	0.10
Yes		1/69 (1.4)	1/81 (1.2)	/	/	0/17 (0.0)	3/14 (21.4)	0.27 (0.03-2.44)		
Readmissions -30d	All patients	74/306 (24.2)	79/298 (26.5)	14/169 (8.3)	9/165 (5.5)	11/117 (9.2)	12/127 (9.3)	0.98 (0.73-1.33)	0.49	
	Gender	Women	39/156 (25.0)	38/163 (23.3)	6/107 (5.6)	5/94 (5.3)	4/59 (6.8)	5/59 (8.5)	1.00 (0.65-1.54)	0.51
		Men	35/150 (23.3)	41/135 (30.4)	8/62 (12.9)	4/71 (5.6)	7/59 (11.9)	7/70 (10.0)	0.98 (0.63-1.50)	
	Source of infection	Non UTI	23/86 (26.7)	23/107 (21.5)	9/68 (13.2)	4/53 (7.5)	4/48 (8.3)	3/63 (4.8)	1.40 (0.82-2.36)	0.46
		UTI	51/220 (23.2)	56/191 (29.3)	5/101 (5.0)	5/112 (4.5)	7/70 (10.0)	9/66 (13.6)	0.82 (0.56-1.19)	
	SBP	SBP≥100	50/215 (23.3)	50/202 (24.8)	8/106 (7.5)	7/117 (6.0)	9/88 (10.2)	7/93 (7.5)	1.07 (0.73-1.55)	0.67
		SBP<100	24/91 (26.4)	29/95 (30.5)	6/63 (9.5)	2/47 (4.3)	2/29 (6.9)	5/34 (14.7)	0.82 (0.49-1.40)	
	Age	Age<65	28/98 (28.6)	27/102 (26.5)	1/28 (3.6)	1/39 (2.6)	3/58 (5.2)	4/59 (6.8)	1.11 (0.65-1.89)	0.82
		Age≥65	46/208 (22.1)	52/196 (26.5)	13/141 (9.2)	8/126 (6.3)	8/61 (13.1)	8/70 (11.4)	0.93 (0.64-1.35)	
	Immunosuppression	No	53/237 (22.4)	51/217 (23.5)	/	/	9/102 (8.8)	10/115 (8.7)	0.99 (0.67-1.47)	0.98
Yes		21/69 (30.4)	28/81 (34.6)	/	/	2/17 (11.8)	2/14 (14.3)	0.79 (0.42-1.51)		

OR – odds ratio; CI – confidence interval; SBP – systolic blood pressure; UTI – urinary tract infection.

Table 3: The association between study arm and outcomes from included studies, stratified by age group, gender, hemodynamic status, immune status, and source of infection.

systolic blood pressure. Nevertheless, sample size of each sub-group may not be sufficient to draw conclusions. Moreover, findings from subgroup analyses are at risk of bias given loss of randomization when considering only subgroups.

Additional limitations of this meta-analysis stem mainly from the inherent limitations of included trials and their external validity. These trials included patients that had ‘uncomplicated bacteremia’ – these were mainly immunocompetent patients, hemodynamically stable and afebrile at time of antibiotic discontinuation, with a controlled infection. For these patients our results are valid. Regarding non-fermenters Gram-negative uncomplicated bacteremia, the number of patients included was limited. Two retrospective studies evaluating therapy duration for uncomplicated *Pseudomonas aeruginosa* bacteremia demonstrated no significant difference in mortality or relapse between short and long courses,^{29,30} however in a recent RCT, 8 versus 15 days of antibiotics for *P. aeruginosa* ventilator associated pneumonia resulted in higher recurrence rate.³¹ Further studies are needed in order to define optimal duration of therapy for *P. aeruginosa* and other non-fermenters bacteremia.

Von-Dach et al. included in their trial a CRP-based duration arm. For patients included in this arm it was allowed to discontinue antibiotics when CRP declined by 75% from peak. Median antibiotic duration in this arm was 7 days (interquartile range, 6–10 days), and all outcomes were non-inferior compared to the 14 days arm.⁶ Future studies should examine biomarker-guided strategy for defining antibiotic duration.

We planned this systematic review as a living systematic review and meta-analysis in light of a large ongoing trial that may provide important additional data on the topic. This trial is currently recruiting patients; and includes patients any bacteremia for the comparison of 7 versus 14 days of antibiotic therapy.¹⁵ Two pilot RCTs were performed to evaluate the feasibility of this trial in ICU and ward patients. These were not included in our meta-analysis, since no relevant outcomes per study arm were reported.^{32,33}

In conclusion, for patients with uncomplicated and controlled Gram-negative bacteremia, 7 days of antibiotic therapy for *enterobacterales* bacteremia result in similar outcomes as 14 days, in terms of mortality, relapse, complications of infection, resistance emergence, and adverse events. These results apply for any adult age group, gender, source of infection, immune status, and hemodynamic status on presentation. Future RCTs should address the duration of therapy for Gram-negative non-fermenters bacteremia.

Contributors

AT, MP, LL and DY conceived the study idea and wrote the protocol for the study. All authors contributed to the review of the final manuscript. EvD, JM, EF, FK, DY, YDB, CM, JRB, JMC, and AH contributed to the

data collection and organization. AT, MP, LL and DY had full access to all the information for the paper and have verified all data included in the review. AT, MP, LL and DY performed the data analysis. AT and DY wrote the draft for the manuscript. All authors reviewed and supervised the manuscript. All authors have read and agreed to the published version of the manuscript.

Data sharing statement

The data that support the findings of this study are not publicly available due to privacy and ethical restrictions. All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Declaration of interests

We declare no competing interests.

Acknowledgments

There was no funding source for this study.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.eclim.2022.101750>.

References

- 1 de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European antimicrobial resistance surveillance system. *Clin Microbiol Infect.* 2013;19:860–868.
- 2 Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y. Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. *Lancet Infect Dis.* 2012;12:480–487.
- 3 Vaughn VM, Flanders SA, Snyder A, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study. *Ann Intern Med.* 2019;171:153–163.
- 4 Spellberg B, Rice LB. Duration of antibiotic therapy: shorter is better. *Ann Intern Med.* 2019;171:210–211.
- 5 Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 Days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. *Clin Infect Dis.* 2019;69:1091–1098.
- 6 von Dach E, Albrich WC, Brunel A-S, et al. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. *JAMA.* 2020;323:2160–2169.
- 7 Molina J, Montero-Mateos E, Praena-Segovia J, et al. Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. *Clin Microbiol Infect.* 2022;28:550–557.
- 8 Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. *Clin Infect Dis.* 2009;49:1–45.
- 9 Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in epidemiologic studies. *J Am Soc Nephrol.* 2008;19:841–843.
- 10 About IPD meta-analyses/ipdma/about-ipd-meta-analyses; 2020. Accessed August 14, 2020.
- 11 Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ.* 2010;340:c221.
- 12 Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. *JAMA.* 2015;313:1657–1665.
- 13 Frequently asked questions/ipdma/frequently-asked-questions; 2020. Accessed August 14, 2020.

- 14 *Living systematic reviews*; 2020. <https://community.cochrane.org/review-production/production-resources/living-systematic-reviews>. Accessed August 15, 2020.
- 15 Sunnybrook Health Sciences Centre. *Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: Randomized Controlled Trial*. [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT03005145); 2019. <https://clinicaltrials.gov/ct2/show/NCT03005145>. Accessed August 13, 2020.
- 16 Harris PNA, McNamara JF, Lye DC, et al. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. *Clin Microbiol Infect*. 2017;23:533–541.
- 17 *Cochrane Handbook for Systematic Reviews of Interventions*./handbook; 2020. Accessed August 14, 2020.
- 18 Lee C-C, Hsieh C-C, Yang C-Y, et al. Short versus long duration antimicrobial treatment for community-onset bacteraemia: a propensity score matching study. *Int J Antimicrob Agents*. 2019;54:176–183.
- 19 Sousa A, Pérez-Rodríguez MT, Suárez M, et al. Short- versus long-course therapy in gram-negative bacilli bloodstream infections. *Eur J Clin Microbiol Infect Dis*. 2019;38:851–857.
- 20 Giannella M, Pascale R, Toschi A, et al. Treatment duration for *Escherichia coli* bloodstream infection and outcomes: retrospective single-centre study. *Clin Microbiol Infect*. 2018;24:1077–1083.
- 21 Doi A, Morimoto T, Iwata K. Shorter duration of antibiotic treatment for acute bacteraemic cholangitis with successful biliary drainage: a retrospective cohort study. *Clin Microbiol Infect*. 2018;24:1184–1189.
- 22 Mercurio NJ, Stogsdill P, Wungwattana M. Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus β -lactams. *Int J Antimicrob Agents*. 2018;51:687–692.
- 23 Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the outcomes of adults with enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. *Clin Infect Dis*. 2018;66:172–177.
- 24 Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. *Infection*. 2017;45:613–620.
- 25 Swamy S, Sharma R. 714Gram negative bacteremia: are shorter courses of antimicrobial therapy feasible? *Open Forum Infect Dis*. 2014;1:S201–S202.
- 26 Uno S, Hase R, Kobayashi M, et al. Short-course antimicrobial treatment for acute cholangitis with Gram-negative bacillary bacteremia. *Int J Infect Dis*. 2017;55:81–85.
- 27 Park SH, Milstone AM, Diener-West M, Nussenblatt V, Cosgrove SE, Tamma PD. Short versus prolonged courses of antibiotic therapy for children with uncomplicated Gram-negative bacteraemia. *J Antimicrob Chemother*. 2014;69:779–785.
- 28 Hojat LS, Bessesen MT, Huang M, et al. Effectiveness of shorter versus longer durations of therapy for common inpatient infections associated with bacteremia: a multicenter, propensity-weighted cohort study. *Clin Infect Dis*. 2020;71:3071–3078.
- 29 Babich T, Naucler P, Valik JK, et al. Duration of treatment for *Pseudomonas aeruginosa* bacteremia: a retrospective study. *Infect Dis Ther*. 2022. <https://doi.org/10.1007/s40121-022-00657-1>. published online May 25.
- 30 Fabre V, Amoah J, Cosgrove SE, Tamma PD. Antibiotic therapy for *Pseudomonas aeruginosa* bloodstream infections: how long is long enough? *Clin Infect Dis*. 2019. <https://doi.org/10.1093/cid/ciz223>. published online March 18.
- 31 Bouglé A, Tuffet S, Federici L, et al. Comparison of 8 versus 15 days of antibiotic therapy for *Pseudomonas aeruginosa* ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. *Intensive Care Med*. 2022. <https://doi.org/10.1007/s00134-022-06690-5>. published online May 13.
- 32 Daneman N, Rishu AH, Pinto R, et al. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. *Trials*. 2018;19:111.
- 33 Daneman N, Rishu AH, Pinto R, et al. A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards. *Trials*. 2020;21:92.